BioSpace News Archive

Lone Star Bio

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

Ziopharm Oncology, Inc. today highlighted recent operational and corporate updates.

January 26, 2022
·
7 min read
Drug Development

Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer

Medicenna Therapeutics Corp. today announced the peer-reviewed publication of preclinical data on MDNA11.

January 26, 2022
·
8 min read
Business

IONETIX and PRECISION MOLECULAR Inc. Announce Supply Agreement for Astatine-211

Agreement secures commerical supply of Astatine-211 to support the clinical development of PMI’s targeted alpha therapies.

January 26, 2022
·
3 min read
Drug Development

BioTheryX Doses First Patient in Phase 1 Study Investigating Lead Protein Degrader Candidate BTX-1188

BioTheryX, Inc. today announced dosing of the first-in human Phase 1 study investigating its lead candidate BTX-1188.

January 26, 2022
·
3 min read
Business

Mednow Awarded 2022 Best Workplace™ - Start-ups

Mednow Awarded 2022 Best Workplace.

January 26, 2022
·
5 min read
Business

PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022

PolyPid Ltd. today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 9, 2022.

January 26, 2022
·
1 min read
BioCapital

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with OrphanDC.

January 26, 2022
·
4 min read
Business

Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast

Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021, and issued its financial outlook for 2022.

January 26, 2022
·
31 min read
Drug Development

Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)

Aligos Therapeutics, Inc. today announced that he first chronic hepatitis B (CHB) patient has been dosed in the multiple ascending dose (MAD) portion of Study ALG-020572-401 (NCT05001022) which is evaluating antisense oligonucleotide (ASO) ALG-020572.

January 26, 2022
·
5 min read
NanoPass’s intradermal delivery platform used in Emergex’s next generation COVID-19 vaccination study

Intradermal COVID-19 vaccination studies are emerging in a global effort to use available doses more effectively by harnessing skin immunity to reduce the dosage required for effective vaccination, as well as to improve the immunogenicity of weaker vaccines.

January 26, 2022
·
4 min read